Zevra Therapeutics (ZVRA – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Jason Butler from JMP Securities reiterated a Buy rating on the stock and has a $18.00 price target.
Jason Butler has given his Buy rating due to a combination of factors including the impressive launch of MIPLYFFA, which has surpassed expectations with strong U.S. sales and full enrollment of active EAP patients. The financial results for the fourth quarter of 2024 exceeded estimates, and the company has a solid cash position projected to last until 2029, providing a stable financial outlook.
Additionally, Zevra Therapeutics is actively expanding globally with plans to submit regulatory applications in the EU by the second half of 2025. The company is also making strategic moves to enhance the growth of OLPRUVA and is progressing with the Phase 3 DiSCOVER trial for Vascular Ehlers-Danlos Syndrome. These efforts, along with potential strategic alternatives for KP1077, contribute to the positive outlook and justify the Buy rating.
In another report released on February 27, Maxim Group also maintained a Buy rating on the stock with a $25.00 price target.
Questions or Comments about the article? Write to editor@tipranks.com